Chiayu Chen
Cardiovascular Disease · Riverside, CANPI 1972583821
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,600 of the $36,539 with a category attached, or 64.6%. Esperion Therapeutics, Inc. accounts for 71.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2021 at $20,449 and has fallen 99.0% since, to $201 in 2024. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $68.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$26K
- Novartis$2K
- Boston Scientific$1K
- Amgen$800
- AstraZeneca$742
- Sanofi-aventis U.S. LLC$682
- plus $5K from 32 others
Across 2 payments — averaging $2387.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$4K
- Eli Lilly$1K
What the payments were for
- Consulting fees$8312%
- Speaking & faculty fees$23,60065%
- Travel & lodging$1,9155%
- Food & beverage$9,81627%
- Education$3771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 54 | $26,161 |
| Novartis | 119 | $2,075 |
| Boston Scientific | 16 | $1,297 |
| Amgen | 70 | $800 |
| AstraZeneca | 40 | $742 |
| Sanofi-aventis U.S. LLC | 21 | $682 |
| Boehringer Ingelheim | 26 | $532 |
| Alnylam Pharmaceuticals Inc. | 12 | $479 |
| Medtronic(2 entities) | 11 | $430 |
| Merck | 21 | $416 |
| Astellas Pharma US Inc | 8 | $384 |
| Johnson & Johnson | 21 | $286 |
| Amarin Pharma, Inc. | 17 | $284 |
| Pfizer | 13 | $282 |
| E.r. Squibb & Sons, L.L.C. | 18 | $273 |
| Abbott | 2 | $161 |
| Bayer | 3 | $160 |
| Regeneron Healthcare Solutions, Inc. | 7 | $134 |
| Kowa Pharmaceuticals America, Inc. | 7 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $100 |
| Novo Nordisk | 6 | $97 |
| Actelion Pharmaceuticals US, Inc. | 5 | $97 |
| Philips North America LLC | 5 | $95 |
| Cvrx, Inc. | 2 | $65 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Biotronik Inc. | 1 | $49 |
| Akcea Therapeutics, Inc. | 2 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Vifor Pharma, Inc. | 2 | $37 |
| Baxter Healthcare | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Infobionic, Inc | 1 | $14 |
| Gilead | 1 | $14 |
| Avinger Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$25,569
- NEXLETOL$25,569
- WATCHMAN Access System$935
- CoreValve Evolut$276
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$141
- Kerendia$125
- ONPATTRO$125
- AMVUTTRA$125
- PRALUENT$106
How this compares
$36,539 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $26,758 |
| EntrestoSacubitril/Valsartan | 21 | $22,997 |
| Repatha SureclickEvolocumab | 13 | $17,471 |
| FarxigaDapagliflozin Propanediol | 14 | $15,135 |
| Praluent PenAlirocumab | 11 | $6,231 |
| Ezetimibe | 91 | $2,538 |
| Rosuvastatin Calcium | 55 | $1,237 |
| Valsartan | 29 | $789 |
| Metoprolol Succinate | 40 | $669 |
| Atorvastatin Calcium | 55 | $600 |
| Irbesartan | 14 | $339 |
| Amlodipine Besylate | 36 | $286 |
| Hydralazine Hcl | 11 | $215 |
| Pantoprazole Sodium | 11 | $211 |
| Spironolactone | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $282 | $26,75819 claims |
| NovartisEntresto | $2,075 | $22,99721 claims |
| AstraZenecaFarxiga | $742 | $15,13514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Riverside
- Patrick HuRiverside$149K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.